Forbes October 17, 2025
In a sweeping set of policy announcements that combine speed with cost control, the U.S. Food and Drug Administration (FDA) and the White House unveiled a new package of measures designed to accelerate access to high-priority medicines and lower their prices.
The centerpiece is the new Commissioner’s National Priority Voucher (CNPV) program, an unprecedented mechanism that shortens FDA review timelines from the usual 10 to 12 months to just one or two months for drugs deemed vital to national interests. Simultaneously, the administration rolled out “most-favored-nation” (MFN) pricing agreements with major pharmaceutical companies—most notably EMD Serono, AstraZeneca and Pfizer—tied to tariff exemptions and access to a new direct-to-consumer drug platform, TrumpRx.
Together, the measures are designed to deliver faster approvals...
Today's Sponsors
Today's Sponsor